hrp0089p1-p166 | Growth & Syndromes P1 | ESPE2018

Safety and Effectiveness of Growth Hormone Treatment in Patients with Prader-Willi Syndrome under 2 Years of Age in a Reference Hospital

Corripio Raquel , Tubau Carla , Cahis Nuria , Perez Jacobo , Rivera Josefa , Gabau Elisabeth

Introduction: Growth hormone (GH) treatment was approved in 2000 for patients with Prader-Willi syndrome (PWS). The main reason for its use was the improvement in body composition. As a result of 2 fatal episodes, it was decided to initiate it from 2 years of age arbitrarily. Average age of real start: 4-6years. GH per se is not a risk factor for mortality in PWS. The 2013 guideline recommends to star it as soon as possible, preferably under 2 years of age, when obesity is est...

hrp0089p2-p245 | Growth & Syndromes P2 | ESPE2018

Clinical Review of Seven Patients Affected with 49,XXXXY Syndrome

Sanchez Jacobo Perez , Collado Raquel Corripio , Escofet Concepcion , Brun Carme , Gabau Elisabeth

Introduction: 49,XXXXY polysomy incidence is about 1 per 85000 to 100000 male births. As a rare condition with medical problems affecting different systems it should be evaluated under a multidisciplinary approach. We have reviewed the clinical characteristics of patients with this anomaly from all the country who contacted the program for evaluation.Methods: In 2016 we started a multidisciplinary program for the care of patients with sex chromosomal ane...

hrp0084p2-170 | Adrenals | ESPE2015

Usefulness of Salivary Cortisol Levels in Secondary Adrenal Insufficiency in Paediatric Population

Corripio Raquel , Perez Jacobo , Borras Ariadna , Capdevila Laura , Sanchez Judith , Rivera Josefa

Background: The main cause of secondary adrenal insufficiency (SAI) in children is prolonged treatment with exogenous corticosteroids. plasma cortisol (PC) levels after administration of ACTH is the most used indicator of adrenal function in clinical practice. However, salivary cortisol (SC) levels is emerging as an alternative technique in the diagnosis of adrenal pathology, especially useful in the paediatric population because it is a simple noninvasive test.<p class="a...

hrp0084p3-699 | Diabetes | ESPE2015

Continuous Intersticial Glucose Monitoring in Early Detection of Glucose Tolerance Abnormalities in Adolescents with Cystic Fibrosis

Perez Jacobo , Corripio Raquel , Belver David , Asensio Oscar , Bosque Montserrat , Rivera Josefa

Background: Cystic fibrosis-related diabetes (CFRD) and glucose abnormalities have a negative impact on pulmonary function and survival in cystic fibrosis (CF) patients. Oral glucose tolerance test (OGGT) is the screening test of choice for CFRD, although undetected high glucose levels can be missed with this test. The use of a continuous intersticial fluid glucose monitoring system (CGM) can be useful in these patients.Objective and hypotheses: To deter...

hrp0094p2-197 | Fat, metabolism and obesity | ESPE2021

Triponderal mass index for the categorisation of childhood obesity on the basis of 58.364 observations of 7.792 patients

Corripio Raquel , Alder Lorna , Perez Jacobo , Sanchez-Garvin Dunia , Rivera Josefa ,

Introduction: childhood obesity constitutes a relevant problem of public health. Body mass index (BMI) is the most used anthropometric parameter for its definition: >2 z-score deviation (SD) according to age and sex for reference charts. Recent studies have proposed triponderal mass index (TMI) to identify metabolic risk by obesity. TMI presents the advantage to be a constant value simplifying the calculations.Aims: determine the use...

hrp0094p2-288 | Growth and syndromes (to include Turner syndrome) | ESPE2021

Comorbidities in Turner Syndrome patients controlled in our center since the 80’s

Corripio Raquel , Vargas Laura , Baena Neus , Garcia Emma , Perez Jacobo , Rivera Josefa ,

Introduction: Turner syndrome (TS) is a genetic condition with different phenotypic expressions depending on karyotype. Due to genetic prenatal testing, its prevalence is getting lower. The objective was to analyze the presence of different comorbidities associated with TS according to the karyotype and evaluate if there is follow-up in adulthood.Methods: Descriptive retrospective study including all the patients genetic...

hrp0086p1-p257 | Diabetes P1 | ESPE2016

Health-Related Quality of Life and its Associated Factors in Children With Type 1 Diabetes Mellitus

Murillo-Valles Marta , Rajmil Luis , Bel-Comos Joan , Perez Jacobo , Corripio Raquel , Carreras Gemma , Herrero Xavier , Mengibar Jose-Maria , Rodriguez-Arjona Dolors , Ravens-Sieberer Ulrike , Raat Hein

Objective: To assess health-related quality of life (HRQOL) in a cohort of children and adolescents with type 1 Diabetes (T1DM) and its associated factors.Methods: This was a descriptive study of 136 patients with T1DM from five hospitals in Catalonia, Spain (72 girls, mean age 13.4 years (range 8–19). Inclusion criteria were more than 6 months from diagnosis, more than 8 years old and without cognitive problems. Sociodemographic (age, sex, family l...

hrp0086rfc15.6 | Late Breaking | ESPE2016

Safety of GH in Paediatrics: The GeNeSIS Prospective Observational Study Experience between 1999 and 2015 (NCT01088412)

Blum Werner , Child Christopher , Chrousos George , Cummings Elisabeth , Deal Cheri , Hasegawa Tomonobu , Holterhus Paul-Martin , Jia Nan , Lawrence Sarah , Linglart Agnes , Loche Sandro , Maghnie Mohamad , Sanchez Jacobo Perez , Polak Michel , Predieri Barbara , Richter-Unruh Annette , Rosenfeld Ron , Tajima Toshihiro , Yeste Diego , Yorifuji Tohru

Background: Although GH’s safety profile since 1987 is good, concerns remain regarding cancer (CA) risk, and French SAGhE data indicated increased mortality and cerebrovascular disease (CVD) in certain GH-treated patients (pts).Objective and hypotheses: To evaluate key safety outcome incidence in GH-treated pts of all short stature diagnoses (dx) who participated in GeNeSIS (1999–2015, 30 countries).Methods: Pt history/ca...